Skip to content
‹ Back to IndustriesHealthcare

The Power of Prescription Drug Monitoring Programs (PDMP) in an American Health Crisis

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

A 2010 national youth drug abuse study revealed some disturbing results. In 2009, the drugs of choice for 6 of 10 drug abusers in the 12th grade were prescription pharmaceuticals. Likewise, data from a 2008 SAMSHA report revealed that the previous decade had seen a four-fold increase in the number of those seeking treatment for addiction to prescription painkillers. In response to the serious public health problem in this country, efforts are underway to combat this growing threat. One solution is the advent of Prescription Drug Monitoring Programs (PDMP).

What is a PDMP?

PDMP is a healthcare tool with a variety of applications. The first PDMP appeared in California in 1939, primarily as a benefit for law enforcement tracking illegal drug behaviors. Today’s PDMP has evolved; as an online database of prescribing and dispensing data, PDMP helps identify when a patient obtains multiple prescriptions from different practitioners. Each database is state-run and used to address prescription drug diversion and abuse. PDMPs serve multiple functions. A PDMP is a patient care tool, a drug epidemic early warning system, and a drug diversion and insurance fraud investigation mechanism. The goal of the PDMP is to reduce the impact of prescription drug abuse and diversion.

Areas of Current and Future PDMP Impact

Not all states have PDMP requirements. Those who currently require health care personnel to utilize this system are Arizona, Connecticut, Maine, Minnesota, New York, Virginia, North Carolina, and Rhode Island. These states are seeing drastically reduced incidences of fraudulent patient behavior.

This is especially true in highly populated states such as New York, where improved visibility into prescribing patterns and potential drug-seeking behaviors has been critical to combating the practice of “doctor shopping,” as described above, in which drug addicts and system abusers go from clinic to clinic amassing a pile of prescriptions for the desired controlled substances. Looking toward the future, 12 states have requirements pending, and the hope is that the 29 states plus DC and Guam who currently have no requirement will decide to follow suit soon.

New York’s successful program has expanded to include access to other state databases and information, and this transparency and interoperability might be a prediction of the future of PDMP.

Overall Benefits

Data regarding PDMP use by state clearly shows positive benefits in the states that use these tools. While research into PDMP effectiveness is ongoing, a 2012 study looked at rates of painkiller abuse and misuse in PDMP vs. non-PDMP states from 2003 to 2009 and discovered that in non-PDMP states, rates of abuse and misuse increased more rapidly than in states with such programs.

But PDMPs are not just concerned with legality. Hand-in-hand with reduced fraudulent and abusive behavior is the improvement of identification of and treatment options for those spiraling in the tornado of the addiction epidemic, perhaps the real crowning achievement of these programs. A hallmark of addiction is a lack of self-awareness and honesty regarding one’s own harmful behaviors, and the PDMP becomes a life-saving tool in which doctors and patients can have the transparent conversations needed to kick-start recovery.

DrFirst and ChartLogic

DrFirst has been at the forefront of electronic prescribing of controlled substances (EPCS) since it sent the nation’s first electronic prescription of a controlled substance. In our partnership with DrFirst, ChartLogic is poised to make a huge impact on this current health crisis as part of a joint effort. The marriage of our software with DrFirst’s program makes sense given the proven success of our ambulatory EHR suite that includes Electronic Medical Records, Practice Management, and Billing Services. And we are proud to be part of a solution that is not only changing lives, but also saving them

Read more at chartlogic.com

Sources:

http://www.chartlogic.com/blog/the-power-of-prescription-drug-monitoring-programs/#_ednref1

https://www.ncjrs.gov/pdffiles1/ondcp/pdmp.pdf

https://searchandrescueusa.org/monitoryourpatients/?utm_source=google&utm_medium=ppc&utm_campaign=2018_PFDK_Nonbrand_PDMP&utm_term=pdmp

https://healthitanalytics.com/news/ny-expands-prescription-drug-monitoring-program-to-25-states

https://www.drugrehab.org/the-benefits-of-prescription-drug-monitoring-programs-pdmp/

https://www.drfirst.com/resources/e-prescribing-mandate-map/

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512